LYR-210 FDA END OF PHASE 2 MEETING HIGHLIGHTS

June 8, 2021



DISCLAIMER



This presentation contains forward-looking statements within the meaning of the private securities litigation reform act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company's clinical advancement of LYR-210 for the treatment of CRS. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company's need for additional funding, which may not be available; the company's limited operating history; the fact that the company has no approved products; the fact that the company's product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company's product candidates satisfy the requirements for the section 505(b)(2) regulatory approval pathway; the company's inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company's reliance on third parties to conduct its preclinical studies and clinical trials; the company's inability to succeed in establishing and maintaining collaborative relationships; the company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company's growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company's business and operations, including the company's clinical trials; the fact that the price of the company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation.

These and other important factors discussed under the caption "risk factors" in the company's quarterly report on form 10-q filed with the SEC on may 11, 2021 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

LYR-210 - FULL STEAM AHEAD

End of Phase 2 Meeting: Clear Path Forward for Phase 3 Program





Key Clinical Highlights

Single primary efficacy endpoint: 3 Cardinal Symptoms at 24 weeks

7500µg dose

~350 subjects split between two staggered studies; >95% power per study

No material change to cost or duration of pivotal program



PK data supports 505(b)(2)


No additional non-clinical studies needed

CMC specs and stability plan sufficient to move forward

A \$6BN MARKET OPPORUNITY

An unmet need for better treatment options exists for millions of CRS patients





1) Young, L. Cet al. Allergy & Rhinology, 2012; 3(1), 8-12

LYR-210

LYR-210 PHASE 3 PRIMARY ENDPOINT


Robust effect on 3 cardinal symptoms: highly statistically significant at week 24

6-month benefit from a single administration

Showed benefit in both polyp and non-polyp patients



CHANGE FROM BASELINE IN 3CS AT WEEK 24^{1,2}



Statistically Significant Improvement vs Control at Weeks 12 - 24

1) Mean change from baseline (CFBL) in the 7-day average score in the 3CS composite score (nasal blockage, facial pain/pressure, and nasal discharge (anterior/posterior); 2) Data represents LSM. P<0.05 is considered statistically significant to control

LYR-210 SAFETY & TOLERABILITY

Well-tolerated throughout the 24-week treatment period at both doses



WELL-TOLERATED SAFETY PROFILE AT BOTH DOSES



No treatment-related SAEs

Treatment-related AE's in more than 1 subject:

- Epistaxis: 3 subjects at 2500 mcg
- Rhinitis: 3 subjects at 7500 mcg
- Rhinorrhea: 2 subjects at 2500 mcg
- Headache: 2 subjects in control



All treatment-related AEs mild or moderate apart from one event:

Increased viscosity of upper respiratory secretion at 2500 mcg



Treatment-related AE's in control and 7500 mcg groups occurred at comparable rates

LYR-210

PERFORMANCE IS HIGHLY COMPETITIVE


 Rapid, durable and clinically
meaningful results based on gold standard measurement

>2X the MCID of 8.9 points relative to control

100% of patients improved ≥ MCID at week 24



POSITIVE PH 2 LANTERN STUDY



*Data from separate trials with different inclusion/ exclusion criteria and patient populations

Sources:

XHANCE: Sindwani, et al., Am J Rhinol Allergy 2019, Vol. 33(1) 69–82; Lepard et al., J Allergy Clin Immunol, 2019;143:126-34 DUPIXENT: Bachert, et al., Lancet 2019; 394: 1638–50 XOLAIR: Gevaert et al, J Allergy Clin Immunol, 2020, 146(3), 595-605



DIFFERENTIATED FROM CURRENT POLYP PRODUCTS



Non-systemic, easy compliance, 6-months via one application, for polyps and non-polyps



Local effect



Requires no patient compliance



For non-polyp & polyp CRS



6-month continuous treatment with one application



